WO2009108372A3 - Antibodies as t cell receptor mimics, methods of production and uses thereof - Google Patents

Antibodies as t cell receptor mimics, methods of production and uses thereof Download PDF

Info

Publication number
WO2009108372A3
WO2009108372A3 PCT/US2009/001290 US2009001290W WO2009108372A3 WO 2009108372 A3 WO2009108372 A3 WO 2009108372A3 US 2009001290 W US2009001290 W US 2009001290W WO 2009108372 A3 WO2009108372 A3 WO 2009108372A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
methods
production
cell receptor
receptor mimics
Prior art date
Application number
PCT/US2009/001290
Other languages
French (fr)
Other versions
WO2009108372A2 (en
Inventor
Jon A. Weidanz
Original Assignee
Receptor Logic, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Receptor Logic, Inc. filed Critical Receptor Logic, Inc.
Priority to EP09715242A priority Critical patent/EP2262834A4/en
Publication of WO2009108372A2 publication Critical patent/WO2009108372A2/en
Publication of WO2009108372A3 publication Critical patent/WO2009108372A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The presently disclosed and claimed invention relates to a methodology of producing and utilizing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies may be utilized in therapeutic methods of mediating cell lysis.
PCT/US2009/001290 2008-02-27 2009-02-27 Antibodies as t cell receptor mimics, methods of production and uses thereof WO2009108372A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09715242A EP2262834A4 (en) 2008-02-27 2009-02-27 Antibodies as t cell receptor mimics, methods of production and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6732808P 2008-02-27 2008-02-27
US61/067,328 2008-02-27
US19187108P 2008-09-12 2008-09-12
US61/191,871 2008-09-12

Publications (2)

Publication Number Publication Date
WO2009108372A2 WO2009108372A2 (en) 2009-09-03
WO2009108372A3 true WO2009108372A3 (en) 2009-11-05

Family

ID=41016658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/001290 WO2009108372A2 (en) 2008-02-27 2009-02-27 Antibodies as t cell receptor mimics, methods of production and uses thereof

Country Status (2)

Country Link
EP (1) EP2262834A4 (en)
WO (1) WO2009108372A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2651510T3 (en) 2011-04-01 2018-01-26 Memorial Sloan-Kettering Cancer Center T-cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2
PT3626729T (en) 2014-12-23 2021-11-03 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
RU2021124437A (en) 2015-04-03 2021-09-29 Еурека Терапьютикс, Инк. CONSTRUCTIONS AIMED AT THE AFP / MHC PEPTIDE COMPLEXES AND THEIR USES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060034850A1 (en) * 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090042285A1 (en) * 2004-05-27 2009-02-12 Weidanz Jon A Antibodies at T cell receptor mimics, methods of production and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007030451A2 (en) * 2005-09-07 2007-03-15 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
CA2656583A1 (en) * 2006-06-01 2007-12-13 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060034850A1 (en) * 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20070092530A1 (en) * 2004-05-27 2007-04-26 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090042285A1 (en) * 2004-05-27 2009-02-12 Weidanz Jon A Antibodies at T cell receptor mimics, methods of production and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANETTE STRYHN ET AL.: "Shared fine specificity between T-cell receptors and an antibody recognizing a peptide/major histocompatibility class I complex", PROC. NATL. ACAD. SCI. USA, vol. 93, September 1996 (1996-09-01), pages 10338 - 10342, XP008143529 *
BINH ET AL.: "Epitopes of the class I major histocompatibility complex (MHC-I) recognized in the syngeneic or allogeneic context predominantly linked to antigenic peptide loading to its binding groove", BRITISH SOCIETY FOR IMMUNOLOGY, CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 145, 2006, pages 372 - 379, XP008143527 *
CYRIL J. COHEN ET AL.: "Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions", J. MOL. RECOGNITION., vol. 16, 2003, pages 324 - 332, XP008050078 *
DENKBERG ET AL.: "Recombinant antibodies with T-cell receptor-like specificity: Novel tools to study MHC class I presentation", AUTOIMMUNITY REVIEWS, vol. 5, 2006, pages 252 - 257, XP024977451 *
DOO HYUN CHUNG ET AL.: "Competitive Inhibition In Vivo and Skewing of the T Cell Repertoire of Antigen-Specific CTL Priming by an Anti-Peptide-MHC Monoclonal Antibody", THE JOURNAL OF IMMUNOLOGY, vol. 167, 2001, pages 699 - 707, XP002903695 *
See also references of EP2262834A4 *
WEIDANZ ET AL.: "Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 318, 2007, pages 47 - 58, XP005820135 *

Also Published As

Publication number Publication date
WO2009108372A2 (en) 2009-09-03
EP2262834A4 (en) 2011-08-17
EP2262834A2 (en) 2010-12-22

Similar Documents

Publication Publication Date Title
IL207449A0 (en) Genetically modified cyanobacteria, methods of producing the same and methods of producing ethanol utilizing the same
IL216861A (en) Nucleic acids encoding polypeptides that bind to activine, gdf8 or gdf11, cultured cells comprising them, polypeptides, pharmaceutical preparations and uses thereof
IL195470A0 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
HRP20160730T1 (en) Methods of modifying antibodies, and modified antibodies with improved functional properties
WO2013151666A3 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
WO2010117957A3 (en) Methods and materials for delivering molecules
WO2013152059A8 (en) Multicolored ph-activatable fluorescence nanoplatform
WO2011062997A3 (en) Human monoclonal antibodies to human nucleolin
WO2013021279A3 (en) Highly galactosylated antibodies
NZ593314A (en) Dual variable domain immunoglobulins and uses thereof
WO2013151665A3 (en) Modified polynucleotides for the production of proteins associated with human disease
WO2011056644A3 (en) Anti-glp-1r antibodies and their uses
WO2014012001A3 (en) Use of cart19 to deplete normal b cells to induce tolerance
EP2286902A4 (en) Separation membrane, method of producing the same and separation membrane module using the separation membrane
MY161909A (en) Anti-her3 antibodies and uses thereof
WO2010040508A8 (en) Bispecific anti-vegf/anti-ang-2 antibodies
WO2011131746A3 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
EP2636642A4 (en) Cnt dispersion liquid, cnt compact, cnt composition, cnt assembly, and method for producing each
IL212066A (en) Anti cxcr4 antibodies, compositions comprising them, processes for their production and selection and use thereof
EP2334330A4 (en) Anti-cd147 antibodies, methods, and uses
MX2010007716A (en) COMBINATION OF AN ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND A MOLECULE BINDING TO B CELLS, B CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART.
LT2510012T (en) Anti-c4.4a antibodies and uses thereof
WO2009111586A3 (en) Autonomous in vitro evolution
WO2010136483A3 (en) Antigen-binding proteins
HK1181056A1 (en) Atelocollagen separation method, method for preparing modified atelocollagen, and atelocollagen-and collagen-based matrix prepared by the methods

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09715242

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009715242

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE